Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024

Cullinan will present new in vitro preclinical data that provide further strong rationale for broad clinical development of CLN-978 in autoimmune diseases

Cullinan will share details of global Phase 1b study in moderate to severe systemic lupus erythematosus

Read more at globenewswire.com